Published Date : 2025-Jul-23
The global gene editing market will continue to grow at its explosive pace until 2025, driven by advancements in CRISPR-Cas systems, increasing therapeutic approvals, rising investments, and expanding agricultural applications.
Major pharma giants are increasing partnerships with biotech startups to accelerate clinical pipelines targeting rare diseases, oncology, and regenerative medicine.
Projected to reach USD 16.18 Billion by 2028, growing at a CAGR of 17.2%.
Here is a list of the leading companies shaping this industry.
The market is projected to surpass $13 billion USD by 2025 with a CAGR of 17.2%.
Asia-Pacific and North America lead in R&D expenditure and clinical trials.
Ex-vivo cell therapies (CAR-T, CAR-NK) and in-vivo gene therapies are hot segments.
Synthetic biology and AI-driven gene editing platforms are emerging.
Ethical debates and biosecurity risks fuel calls for robust governance.
⇒ Would you like me to add more details on specific companies or market trends? Let me know! CLICK HERE
Rising prevalence of genetic disorders
Breakthroughs in CRISPR, TALEN, ZFN technologies
Strategic M&A and venture capital inflow
Growing adoption in agriculture and livestock
Favorable regulatory frameworks for genome editing therapies
Headquarters: Zug, Switzerland
Founded: 2013
Employees: Approx. 500+
Revenue 2025 : Approx. $480 million
CRISPR Therapeutics is a leading gene-editing company pioneering transformative, potentially curative therapies using its proprietary CRISPR/Cas9 platform technology. It was co-founded by Nobel Prize-winning scientist Emmanuelle Charpentier, a co-inventor of the CRISPR-Cas9 gene-editing tool.
Headquarters: Cambridge, MA, USA
Founded: 2013
Employees: Approx. 250+
Revenue 2025 : Approx. $180 million
Editas Medicine is a clinical-stage biotechnology company pioneering gene-editing medicines to treat a broad range of serious diseases. It was founded by scientific leaders who helped develop CRISPR-Cas9 and CRISPR-Cas12a technologies, including Feng Zhang, George Church, and Jennifer Doudna.
Headquarters: Cambridge, MA, USA
Founded: 2014
Employees: Approx. 400+
Revenue 2025 : Approx. $360 million
Intellia Therapeutics is a leading genome-editing biotechnology company focused on developing in-vivo and ex-vivo CRISPR therapies. Co-founded by Jennifer Doudna — one of the Nobel Prize-winning inventors of CRISPR-Cas9 — Intellia has delivered multiple industry firsts in systemic CRISPR administration for genetic diseases.
Headquarters: Brisbane, CA, USA
Founded: 1995
Employees: Approx. 280+
Revenue 2025 : Approx. $75 million
Sangamo Therapeutics is a genomic medicine company pioneering gene-edited cell and gene therapies. Unlike some peers that focus exclusively on CRISPR, Sangamo is known for its proprietary Zinc Finger Nuclease (ZFN) technology — one of the first gene-editing platforms applied clinically. The company develops in-vivo and ex-vivo genomic therapies for rare diseases, neurology, immunology, and hemophilia.
Headquarters: Durham, NC, USA
Founded: 2006
Employees: Approx. 150+
Revenue 2025 : Approx. $50 million
Precision BioSciences is a clinical-stage biotechnology company developing allogeneic CAR T cell therapies and gene correction treatments using its proprietary ARCUS® genome editing platform. Unlike CRISPR or ZFN, ARCUS is derived from a naturally occurring homing endonuclease, I-CreI, enabling highly precise and compact gene edits.
Headquarters: Cambridge, MA, USA
Founded: 2017
Employees: Approx. 300+
Revenue 2025 : Approx. $110 million
Beam Therapeutics is a pioneering biotechnology company specializing in base editing, a next-generation gene editing technology that enables single-letter (nucleotide) edits to DNA and RNA without cutting both DNA strands like traditional CRISPR. This approach allows for highly precise corrections to disease-causing mutations.
Beam was co-founded by David Liu, a key inventor of base editing, and Feng Zhang, a CRISPR pioneer — both from the Broad Institute.
Headquarters: Somerville, MA, USA
Founded: 1992
Employees: Approx. 350+
Revenue 2025 : Approx. $50 million
Bluebird Bio is a biotechnology company best known for pioneering gene therapy for severe genetic diseases and certain cancers. Unlike other companies focused purely on CRISPR editing, Bluebird’s approach centers around lentiviral vector-based gene addition — inserting functional copies of defective genes into a patient’s cells. They are also advancing innovative cell-based immunotherapies.
Headquarters: Cambridge, UK
Founded: 2007
Employees: Approx. 400+
Revenue 2025 : Approx. $90 million
Horizon Discovery, now part of Revvity Inc. (formerly PerkinElmer), is a leading provider of gene editing and gene modulation tools, services, and reagents. Unlike therapeutic biotech companies, Horizon’s focus is primarily research solutions — empowering labs worldwide to engineer cells, discover targets, and validate gene function using advanced genome editing platforms.
Horizon’s strength lies in its expertise in CRISPR-Cas9, RNAi, and custom cell line engineering, enabling academic labs, biotech, and pharma companies to accelerate drug discovery and precision medicine R&D.
Headquarters: Berkeley, CA, USA
Founded: 2011
Employees: Approx. 150+
Revenue 2025 : Approx. $30 million
Caribou Biosciences is a clinical-stage biotechnology company developing next-generation CRISPR-based genome-edited allogeneic (off-the-shelf) cell therapies for treating cancer. It was co-founded by Jennifer Doudna — a co-inventor of CRISPR-Cas9 and Nobel Laureate — and is one of the early spinouts commercializing CRISPR genome editing.
Caribou’s edge comes from its CRISPR hybrid RNA-DNA (chRDNA) platform, designed to improve editing precision and specificity over traditional CRISPR-Cas9.
Paris, France & NY, USA
Founded: 1999
Employees: Approx. 300+
Revenue 2025 : Approx. $20 million
Cellectis is a clinical-stage biopharmaceutical company that develops allogeneic, gene-edited CAR-T cell therapies for treating cancers. Cellectis has been a pioneer in the field of TALEN® gene editing (Transcription Activator-Like Effector Nucleases), an alternative to CRISPR and ZFN technologies.
Unlike autologous CAR-T therapies (made from each patient’s own cells), Cellectis develops off-the-shelf, donor-derived CAR-T cell products, aiming to make immunotherapies more scalable and accessible.
Tropic Biosciences is a pioneering agricultural biotech company specializing in gene editing for tropical crops. Using CRISPR and proprietary gene editing technologies, Tropic aims to improve high-value crops like bananas, coffee, and rice — boosting disease resistance, yield, and sustainability in key food systems that feed billions.
Tropic is best known for its Gene Editing Induced Gene Silencing (GEiGS®) platform, which combines gene editing with RNA interference to modulate gene expression without altering the genome directly — a clever regulatory workaround in some markets.
Each is pioneering novel gene editing modalities, from CRISPR diagnostics to genome recoding and next-gen base editing.
North America dominates with robust funding, top academic hubs, and leading biotech clusters.
Europe sees strong R&D from the UK, Germany, and France with supportive policy frameworks.
Asia-Pacific (China, Japan, South Korea) accelerates agricultural gene editing and human therapeutics.
Latin America & Africa show emerging biotech zones focusing on crop improvement.
By Technology: Restriction Enzymes: the Original Genome Editor, Zinc Finger Nucleases (ZFNs): Increased Recognition Potential, TALENs Gene Editing: Single Nucleotide Resolution, CRISPR-Cas9 Gene Editing: Genome Editing Revolutionized, Others.
By Application: Cell Line Engineering, Vaccine development, Diagnosis, Animal Genetic Engineering, Plant Genetic Engineering, Other Applications.
By End User: Biotechnology & Pharmaceutical Companies, Diagnostic Centres, Academic & Government Research Institutes, Contract Research Organizations.
The gene editing industry in 2025 is defined by rapid innovation, strategic collaborations, and expanding therapeutic pipelines. Leaders and startups alike are pushing the frontier of what’s possible — from rare genetic disease cures to climate-resilient crops. The race to precision, affordability, and safety will continue to shape its future.
Q1: What is the gene editing market worth in 2025?
Answer: Estimated at $13+ billion with Approx. 17.20% CAGR.
Q2: Which technology leads?
Answer: CRISPR-Cas9 remains dominant, with base and prime editing rapidly growing.
Q3: Who are the top players?
Answer: CRISPR Therapeutics, Editas, Intellia, Sangamo, and others lead globally.
Q4: What are the risks?
Answer: Bioethics, off-target effects, regulatory hurdles, and dual-use biosecurity.
Q5: Which regions lead?
Answer: North America and Asia-Pacific are top R&D hubs.
#GeneEditing #CRISPR #BiotechStartups #SyntheticBiology #GeneticEngineering #LifeSciences #Genomics #BioInnovation #CellTherapy #Biotech2025
IMIR Market Research is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including, Semiconductor, aerospace, Automation, Agriculture, Food & Beverages, Automotive, Chemicals and Materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports.
Contact Us: IMIR Market Research Pvt. Ltd.
Email: sales@intellectualmarketinsights.com
Call Us: +1 (814) 487 8486
